Re‐evaluating age‐related attention‐deficit/hyperactivity disorder (ADHD) symptom trajectories using the Japanese ADHD Rating Scale‐5

Our findings using the ADHD-RS-5 showed results consistent with previous reports regarding age-specific symptom characteristics of ADHD, while also providing new insights into treatment options for ADHD. Clinicians may consider both symptom severity and functional impact when initiating pharmacotherapy. Given medication approval from age 6 in Japan, accurate assessment and diagnosis remain essential, and the ADHD-RS-5 may support decision-making when interpreted alongside clinical judgment and multi-informant input.